EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation

医学 淋巴瘤 移植 干细胞 化疗 免疫学 T细胞 胃肠病学 内科学 骨髓 造血干细胞移植 肿瘤科 免疫系统 生物 遗传学
作者
Lauren P. McLaughlin,Rayne Helen Rouce,Stephen M Gottschalk,Vicky Torrano,George Carrum,Meng‐Fen Wu,Fahmida Hoq,Bambi Grilley,Andrea M. Marcogliese,Patrick J. Hanley,Adrian P. Gee,Malcolm K. Brenner,Cliona M. Rooney,Helen Elisabeth Heslop,Catherine M. Bollard
出处
期刊:Blood [Elsevier BV]
卷期号:132 (22): 2351-2361 被引量:76
标识
DOI:10.1182/blood-2018-07-863654
摘要

Autologous T cells targeting Epstein-Barr virus (EBV) latent membrane proteins (LMPs) have shown safety and efficacy in the treatment of patients with type 2 latency EBV-associated lymphomas for whom standard therapies have failed, including high-dose chemotherapy followed by autologous stem-cell rescue. However, the safety and efficacy of allogeneic donor-derived LMP-specific T cells (LMP-Ts) have not been established for patients who have undergone allogeneic hematopoietic stem-cell transplantation (HSCT). Therefore, we evaluated the safety and efficacy of donor-derived LMP-Ts in 26 patients who had undergone allogeneic HSCT for EBV-associated natural killer/T-cell or B-cell lymphomas. Seven patients received LMP-Ts as therapy for active disease, and 19 were treated with adjuvant therapy for high-risk disease. There were no immediate infusion-related toxicities, and only 1 dose-limiting toxicity potentially related to T-cell infusion was seen. The 2-year overall survival (OS) was 68%. Additionally, patients who received T-cell therapy while in complete remission after allogeneic HSCT had a 78% OS at 2 years. Patients treated for B-cell disease (n = 10) had a 2-year OS of 80%. Patients with T-cell disease had a 2-year OS of 60%, which suggests an improvement compared with published posttransplantation 2-year OS rates of 30% to 50%. Hence, this study shows that donor-derived LMP-Ts are a safe and effective therapy to prevent relapse after transplantation in patients with B cell- or T cell-derived EBV-associated lymphoma or lymphoproliferative disorder and supports the infusion of LMP-Ts as adjuvant therapy to improve outcomes in the posttransplantation setting. These trials were registered at www.clinicaltrials.gov as #NCT00062868 and #NCT01956084.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ish完成签到,获得积分10
刚刚
哈哈哈完成签到,获得积分10
1秒前
245114STP发布了新的文献求助10
4秒前
jz完成签到 ,获得积分10
6秒前
see完成签到,获得积分10
6秒前
xuexi完成签到,获得积分10
7秒前
jfj完成签到,获得积分10
8秒前
8秒前
8秒前
小六子完成签到,获得积分10
9秒前
科研通AI6.3的应助被一只贝果采纳,获得10
9秒前
zjh完成签到,获得积分10
9秒前
10秒前
10秒前
夕茟完成签到,获得积分10
11秒前
guoguo发布了新的文献求助20
12秒前
zhao发布了新的文献求助10
13秒前
漫漫发布了新的文献求助10
13秒前
13秒前
Hale完成签到,获得积分10
13秒前
13秒前
tn完成签到,获得积分10
14秒前
豆花鱼驳回了DW的应助
14秒前
大鸭完成签到 ,获得积分10
15秒前
15秒前
16秒前
16秒前
17秒前
chunfengfusu的应助被土豪的城采纳,获得10
18秒前
1024504036发布了新的文献求助10
18秒前
1893完成签到,获得积分10
18秒前
秋风的应助被小孙采纳,获得20
18秒前
无名的喧嚣完成签到,获得积分10
19秒前
moriaty发布了新的文献求助10
19秒前
一只贝果完成签到,获得积分20
19秒前
19秒前
sunrase完成签到,获得积分10
20秒前
顾矜的应助被Eric采纳,获得10
21秒前
HIJKLXLKJIH完成签到,获得积分10
22秒前
小君君完成签到,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181498
求助须知:如何正确求助?哪些是违规求助? 9571421
关于积分的说明 21817968
捐赠科研通 7777967
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479552